%PDF-1.4
%
36 0 obj
<>
endobj
33 0 obj
<>
endobj
132 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-10-07T18:00:41Z
2024-03-28T08:37:22-07:00
QuarkXPressª: AdobePS 8.8.0 (301)
2024-03-28T08:37:22-07:00
application/pdf
Heather
2003-358.nov
uuid:4e5ed702-1dd2-11b2-0a00-d709277d8900
uuid:4e5ed705-1dd2-11b2-0a00-d30000000000
endstream
endobj
22 0 obj
<>
endobj
23 0 obj
<>
endobj
37 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 10 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 12 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 14 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 16 0 R/Type/Page>>
endobj
148 0 obj
[152 0 R]
endobj
149 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.85091 0.85091 0.85091 rg
/T1_0 19 Tf
0.6229 0.7822 -0.7822 0.6229 12.739 54.1879 Tm
(Personal non-commercial use only. The Journal of Rheumatology. Copyright\
\251 2004. All rights reserved)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 10 0 0 10 55 733.8264 Tm
(REFERENCES)Tj
/T1_2 1 Tf
0.02499 Tw 8 0 0 8 62 723.8264 Tm
[(1.)-875.1 (Schneider R, Passo MH. Juvenile rheumatoid arthritis. Rheum Dis)]TJ
0 Tc 1.675 -1.25 Td
[(Clin N )54.8 (Am 2002;28:503-30.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(2.)-875.1 (Savolainen HA, Isom\212ki HA. Decrease in the number of deaths)]TJ
1.675 -1.25 Td
(from secondary amyloidosis in patients with juvenile rheumatoid)Tj
0 -1.25 TD
(arthritis. J Rheumatol 1993;20:1201-36.)Tj
-1.675 -1.25 Td
[(3.)-875.1 (Oen K. Long-term outcomes and predictors of outcomes for)]TJ
1.675 -1.25 Td
(patients with juvenile idiopathic arthritis. Best Pract Res Clin)Tj
T*
(Rheumatol 2002;16:347-60.)Tj
-1.675 -1.25 Td
[(4.)-875.1 (Murray KJ, Lovell DJ. )54.8 (Advanced therapy for juvenile arthritis. Best)]TJ
1.675 -1.25 Td
(Pract Res Clin Rheumatol 2002;16:361-78.)Tj
-1.675 -1.25 Td
[(5.)-875.1 (Ilowite NT)73.9 (. Current treatment of juvenile rheumatoid arthritis.)]TJ
1.675 -1.25 Td
(Pediatrics 2002;109:109-15.)Tj
-1.675 -1.25 Td
[(6.)-875.1 (W)79.9 (oo P)110.7 (,)-0.1 ( Southwood )17.7 (TR, Prieur )54.8 (AM, et al. Randomized, )]TJ
1.675 -1.25 Td
(placebo-controlled, crossover trial of low-dose oral methotrexate in)Tj
T*
[(children with extended oligoarticular or systemic arthritis. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 2000;43:1849-57.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(7.)-875.1 (Ruperto N, Murray KJ, Gerloni )17.7 (V)128.9 (, et al. )54.8 (A)-220.1 (randomized trial of)]TJ
1.675 -1.25 Td
(parenteral methotrexate comparing an intermediate dose with a)Tj
T*
(higher dose in children with juvenile idiopathic arthritis who failed)Tj
T*
[(to respond to standard doses of methotrexate. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(2004;50:2191-201.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(8.)-875.1 (Martini )54.8 (A. Etanercept improves active polyarticular juvenile)]TJ
1.675 -1.25 Td
(rheumatoid arthritis. Clin Exp Rheumatol 2001;19:122-4.)Tj
-1.675 -1.25 Td
[(9.)-875.1 (Lovell DJ, Giannini EH, Reif)17.7 (f )54.8 (A, et al. Etanercept in children with)]TJ
1.675 -1.25 Td
(polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology)Tj
T*
(Collaborative Study Group. N Engl J Med 2000;342:763-9.)Tj
30.7 32.671 Td
[(10.)-875.1 (Cummins C, Connock M, Fry-Smith )54.8 (A, Burls )54.8 (A. )54.8 (A)-220.1 (systematic)]TJ
2.175 -1.25 Td
[(review of ef)17.7 (fectiveness and economic evaluation of new drug )]TJ
T*
(treatments for juvenile idiopathic arthritis: etanercept. Health)Tj
-0.0298 Tw T*
[(T)69.9 (echnol Assess )-54.8 (2002;6:1-43.)]TJ
0.02499 Tw -2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Schmeling H, Mathony K, John )17.7 (V)128.9 (, Keysser G, Burdach S, Hornef)17.7 (f)]TJ
2.1381 -1.25 Td
[(G. )54.8 (A)-220.1 (combination of etanercept and methotrexate for the treatment)]TJ
T*
[(of refractory juvenile idiopathic arthritis: a pilot study)64.8 (. )54.8 (Ann Rheum)]TJ
T*
(Dis 2001;60:410-2.)Tj
-2.175 -1.25 Td
[(12.)-875.1 (T)69.9 (en Cate R)59.7 (T)74 (, van Suijlekom-Smit L)73.9 (W)91.9 (, Brinkman DM, Bekkering)]TJ
2.175 -1.25 Td
[(WP)110.7 (, Jansen-van )17.7 (W)39.9 (ijngaarden CJ, )17.7 (V)128.9 (ossen JM. Etanercept in four)]TJ
T*
(children with therapy-resistant systemic juvenile idiopathic )Tj
T*
(arthritis. Rheumatology 2002;41:228-9.)Tj
-2.175 -1.25 Td
[(13.)-875.1 (Kietz DA, Pepmueller PH, Moore )17.7 (TL. )17.7 (Therapeutic use of )]TJ
2.175 -1.25 Td
(etanercept in polyarticular course juvenile idiopathic arthritis over)Tj
T*
[(a two year period. )54.8 (Ann Rheum Dis 2002;61:171-3.)]TJ
-2.175 -1.25 Td
[(14.)-875.1 (Haapasaari J, Kautiainen H, Hakala M. Good results from )]TJ
2.175 -1.25 Td
(combining etanercept to prevailing DMARD therapy in refractory)Tj
T*
(juvenile idiopathic arthritis. Clin Exp Rheumatol 2002;20:867-70.)Tj
-2.175 -1.25 Td
[(15.)-875.1 (Ylijoki H. Re-evaluation on the factors determining the long-term)]TJ
2.175 -1.25 Td
(clinical outcome of juvenile rheumatoid arthritis [Doctoral thesis].)Tj
T*
[(Studies in Social Security and Health 31. )17.7 (T)35 (urku: Social Insurance)]TJ
T*
(Institution; 1998.)Tj
-2.175 -1.25 Td
[(16.)-875.1 (Heikkinen K, Hujanen )17.7 (T)74 (, Rusama H. )17.7 (T)69.9 (erveydenhuollon)]TJ
0 Tc 2.175 -1.25 Td
[(yksikk\232kustannukset Suomessa vuonna 2000. )54.8 (Aiheita -monistesarja)]TJ
-0.00011 Tc T*
(23/2001. Helsinki: National Research and Development Centre for)Tj
T*
[(W)79.9 (elfare and Health.)]TJ
ET
0 0 0 1 K
53.468 76.5 m
558.468 76.5 l
S
0 0 0 0 k
494.29 69.365 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_3 1 Tf
0 Tc 0 Tw 8 0 0 8 541.468 56.4344 Tm
(2289)Tj
ET
0 0 0 0 k
53.532 70.5 203 -15.665 re
f*
BT
0 0 0 1 k
/T1_3 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.532 57.5695 Tm
[(Haapasaari, et al: Etaner)36.8 (cept for JIA)]TJ
ET
0 0 0 0 k
/GS0 gs
103.75 82.583 407.5 -10.833 re
f*
0.5 w
/GS1 gs
103.75 82.583 407.5 -10.833 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_4 8 Tf
112.368 73 Td
(Personal, non-commercial use only. The Journal of Rheumatology. Copyri\
ght \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
16 0 obj
<>stream
8;Z\5d:1$:#kS(GOPe_l+\>nGQ#//n\N@!s$6^NL/,UQt^gb.3q"Zq)A*NNil'>tK
a.M8AfTc9shnI=<'97_<1sk_(*b;pOl;KG[da2$e?)WXW5!\1@&M%N&HhZFdpI2U1
.Imu@5R]=*=F6%;ghnf+0+iXkNtA1eM^cE^niL3h;.CZh
Mept=JPQhI9&7(u`H*akp!E<*keJ],-?*]Uo1Eh\*Atb:aLal/PYNM[3fJ]?1P?tj
7lK3m_2S>p[B&hu/Mn5g.EOXE"r'Jji.Lg:Xl"'g@LA!8&uSrD?B*3B:/a3r\99L$
Np0E9P;=&h9_ok(Aq.-5\WmL@4/'tPfSnQ`lYLd]$ACg?:ad"bKgMJ0ph@)
endstream
endobj
20 0 obj
[/Indexed/DeviceRGB 255 19 0 R]
endobj
19 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
87 0 obj
<>
endobj
63 0 obj
<>
endobj
43 0 obj
<>
endobj
41 0 obj
<>
endobj
78 0 obj
<>
endobj
138 0 obj
<>
endobj
44 0 obj
<>
endobj
71 0 obj
<>stream
HUiPSY~M.=jDdܪU@DYi$, & bAniwDmqzfzrҗhϟ?S[N.`8
RGw1N3MYf2kaւdaʸZء(/fK;_-igT]s^tq&?1IYs#>X?fAaVUpc`KL0
qql Ƣpæ0lq{v,KxΘl3!>wA*ɇuaߛ)GJi-_tu)%vKTUlK_[J,g>kMMyE]]DzeN1`s'.MvN5"MȓuZaNj0OJR[ajeA)i.S YYv[358Q)1[ş Olg(F͠zSxU'=To=u/WQ>du,$6K*_ץ_{
.9x7 q4l-h?75N4Uqdx~`'1њǔwNVպ3n,Tx?vt%ۼY/sO
E&5JEUa^ᜰH cƖ=T0@56>PZ6[͑J%
Ks>%Su ?HTznQB'J=\Kfu/#mib eJ^/Wx}l09C0\vzuKyGa}vXa7rHq@)9Wzex+y8%N8@46
j4KټGeC+h;-ԋN躦BFj+*lFAZyV~0ALP爾NPx\-B8c'Q/7&IX+9)1WWؗL""GȾ3z([x*uAzEA8}/#/,<Eגg!̓zWs?.`[[z)S'KtqRT٘!y"ĎFVy+S7jVq+4T8e%X¦j`w5dNM3UX-"
J
+'`>P|3eow%:|{9xʠ;xJB!2l2Z HgIwܿNoFW.b
>-@t\~,W]SXR1MAm|IgcmLBZl@Y9jECԂCZ,9İu@n0Ғ(+~2_p +Zl5&"ׅ
2@^j$2} 6`}1;튦B75=χӶZPR[VިlQLVyUsCː¾OU
$6{'GRvvMe1L?9%Hw&^\ۚGUPyʯ=yT߮T5|oƫ53
99J6Ԩݢ36xRkUp)"r
!7! b@HHrrBDE0WAZ/xYκw8J>>}ϑ}I]>3Ng/|p:tceě!ҬF
,
lo`,r n>#_ZS[d#KY?K43qiyP)^ZZ;Y3 "<HXFz
n}o((11HRSvyp+a,'©:5Xe<ЇZDh:rO`ə̦dORxz(dB$ 9~U[
2|Y)NRDiU81\'\l:'g
4kTaoZ7Ua(à߀swT+*pd@b=] k_y2{zl}~V[˜s8r!dܖ>(˖6zz}fo6 *,|nA]3V3Op__ʛ(fDő.P[pVwաaN9YŤoLHc&PsK*IKHX95fALZ5.ö)
R'̠}]&[uSSЏ9꿤,K) DG+ot`$} a9=F2NWOzM_iqt
-mg
!3amZ-h*[x`ɞc /t%
eMGUHc͢${!o'it,b;V@`hȟ)-e==i8#۬Pg,gk8ۍn>[}%Z!wR:MϪb dIN:rFJT烸h=ڂp1G?
Z,mKT_YI4?]j.*1zuzmFPώ)b%e#Ť0>[U4C*Vܯ?jmR,q(M2HzqȖ_LZ-H8>}60+| S97bZ5-]IZ "XԠ;"6(hkցvXP{xKbM1u3j0x 8nfq6EWUv䨤LMIaRr-EG(Rd*8GF[V][k,